Prostate cancer (PCa) is the most common visceral malignancy and the second leading cause of cancer deaths in men in the United States. There is compelling evidence both from studies of human tumor samples and from animal models that fibroblast growth factors (FGFs) and FGF receptors (FGFRs) are important in PCa initiation and progression. In this study we demonstrate that inhibition of FGFR signaling using a novel small molecule inhibitor inhibits PCa cell invasion in vitro and tumor progression in vivo. These results indicate that targeting FGFR signaling is a promising new therapeutic approach for treating aggressive PCa. 
STATEMENT OF CLINICAL RELEVANCE
Prostate cancer (PCa) is the most common visceral malignancy and the second leading cause of cancer deaths in men in the United States. There is compelling evidence both from studies of human tumor samples and from animal models that fibroblast growth factors (FGFs) and FGF receptors (FGFRs) are important in PCa initiation and progression. In this study we demonstrate that inhibition of FGFR signaling using a novel small molecule inhibitor inhibits PCa cell invasion in vitro and tumor progression in vivo. These results indicate that targeting FGFR signaling is a promising new therapeutic approach for treating aggressive PCa. FGFs play a key role in the growth and maintenance of normal prostatic epithelium and are expressed in normal prostatic stroma (reviewed in ( (1)). FGFs are expressed as autocrine growth factors by PCa cells (4) and can also be expressed in the tumor microenvironment as paracrine growth factors (5) (6) . Multiple FGF ligands are expressed at increased levels in PCa (1, (4) (5) (7) (8) (9) and increased expression has been shown to be associated with clinically aggressive disease (7, (10) (11) . Recent studies have shown high expression of FGF8 (10) and FGF9 (9) in PCa bone metastases. In all PCa cell lines examined to date one or more FGFs is expressed as an autocrine growth factor ((1) and unpublished data).
Our laboratory has shown that FGFR-1 is expressed in 20% of moderately differentiated cancers and 40% of poorly differentiated localized PCas based on immunohistochemistry (IHC) (5) and other groups have made similar observations (12) (13) . Studies in transgenic mice have linked FGFR-1 activation to cancer initiation and progression (14) (15) (16) and chronic FGFR-1 activation can lead to adenocarcinoma and epithelial-mesenchymal transition (17).
Changes in alternative splicing of FGFR-2 in PCa that enhance oncogenic signaling are well known. It has been shown by several groups (8, (18) (19) including ours (20) (21) . FGFR-3 appears to play a less important role in PCa based on current data (21) .
FGFR-4 is expressed at increased levels in PCa by IHC and this has been verified by quantitative RT-PCR (7, (21) (22) (23) . Strong FGFR-4 expression is significantly associated with poor clinical outcome (7, 22) . For example, Murphy et al (7) have shown that increased FGFR-4 expression is strongly associated with PCa specific death. Our group has shown that a germline polymorphism in the FGFR-4 gene, resulting in expression of FGFR-4 containing arginine at codon 388 (Arg 388 ), instead of a more common glycine (Gly 388 ), is associated with PCa incidence, recurrence after radical prostatectomy and metastatic disease (23) . This allele was present in almost half of white PCa patients. These findings have been confirmed in a similar case control study (24) and in a meta-analysis of all published studies (25) . Expression of the FGFR-4 Arg 388 protein results in increased motility and invasion and is associated with prolonged receptor stability after ligand activation (23) . In recently published studies we have shown that FGFR-4 expression leads to increased activity of the extracellular signal-related kinase (ERK) pathway, increased activity of serum response factor and AP-1 and transcription of multiple genes which are correlated with aggressive clinical behavior in PCa (26) . Finally, several groups, including ours, have shown that decreased expression of negative regulators of FGF signaling is common in human PCa and in some cases these alterations have been shown to be associated with aggressive disease (7, (27) (28) (29) (30) (31) for FGFR-4 is >1000 nM (34) . The only other kinase inhibited at less than 500 nM by AZD4547 was VEGFR2 (IC50 258 nM in HUVEC cells). A recent report shows potent in vitro and/or in vivo activity of AZD4547 against cell lines from myeloid leukemia, myeloma and breast cancer (33) . We show here that AZ8010 potently inhibits FGFR signaling, invasion in vitro and tumor growth in vivo in prostate cancer cells. These findings support the hypothesis that targeting FGFR signaling is a promising therapeutic approach to treating prostate cancer. Author Manuscript Published OnlineFirst on May 9, 2012; DOI: 10.1158/1078-0432.CCR-11-3214 mM, Triton X-100 1%, SDS 0.1%, deoxycholate 0.5%, 2 mM sodium orthovanadate, 1mM sodium pyrophosphate, 50mM NaF, 5 mM EDTA, 1 mM PMSF and 1x protease inhibitor cocktail (Roach) and clarified by centrifugation. The protein concentrations of the lysates were determined using a BCA protein assay kit (Thermo Scientific). Western blots were performed as described previously (26) . The antibodies were from Cell Signaling and included phospho-FGFR mouse monoclonal antibody (mAb, #3476) (26), phospho-p44/42 MAPK (p-Erk1/2) (#4370), p44/42 MAPK (Erk1/2) (#4695), phospho-MEK1/2 (#9154), MEK1/2 (#9122), phospho-AKT (T308, #4056 ), phospho-AKT (S473, #9271) and ȕ-Tubulin (#2128) which were all used at 1:1000 dilution. ȕ-actin mAb (Sigma A5316) was used at 1:5000 dilution. After incubation with primary antibodies for overnight at 4ºC, horseradish peroxidase-labeled secondary antibodies were then applied to the membranes for 1 h at room temperature. Signals were visualized using enhanced chemiluminescence (Thermo).
To detect phosphorylated FGFR-1 in tumor extracts, immunoprecipitation assays were Following incubation for 1 hour at 4°C, the lysate/antibody/agarose mixture was centrifuged at 1000xg for 5 minutes at 4ºC and the pellets were washed 4 times with 1.0 ml of RIPA buffer.
Pellets were eluted in 40 μl of electrophoresis sample buffer and analyzed by Western blotting as described above with mouse anti-phospho-FGFR mAb (1:1000, Cell Signaling).
Densitometry was performed using Image J program (National Institute of Health).
Subcutaneous VCaP xenografts. 30 nude male mice (6-7 weeks old) were purchased from Charles River Laboratories International, Inc. and each animal was injected subcutaneously with Committee.
Immunohistochemistry. IHC of mouse tissues was performed using the basic procedures described previously (28) . Primary antibodies were used as follows: Ki67 (Thermo, RM-9106) at 1:400 for 30 minutes at room temperature and mouse anti-CD31 (BD Biosciences) at 1:10 overnight at 4 o plus 3 hours at room temperature. TUNEL was performed using an ApopTag Peroxidase In Situ Apoptosis Kit (Millipore) according to the manufacturer's instructions. Image analysis of stained sections was performed as described previously (36) . Ki-67 and TUNEL were also carried out on cells grown on chamber slides and quantitated in a similar manner.
Quantitative RT-PCR. Copy numbers of all four FGFRs in prostate and PCa cell line RNAs was determined using quantitative RT-PCR using general procedures described previously (37).
Primers and PCR conditions for FGFR-4 have been described. Primers and conditions for FGFR 1-3 are shown in Supplementary Table 1 . In all cases exact copy number was determined in duplicate samples using a standard curve generated using purified PCR product cloned into plasmid or full length cDNA. HPRT levels were determined as described previously(6) and used to normalize expression levels across cell lines (Fig 2A) . This is equivalent to the 86% inhibition of FGFR-1 phosphorylation seen at 1000 nM AZ8010. ERK phosphorylation was also markedly inhibited (by 78% and 84%) at 100 and 1000 nM, respectively. In PNT1a cells overexpressing FGFR-4, phosphorylation was very significantly inhibited at 100 nM (75% by quantitative densitometry) although inhibition was somewhat less than that seen at 500 nM, which inhibits 89% of FGFR-4 phosphorylation (Fig 2B) . More
Research. AZ8010 FGFR-1 is markedly inhibited and FGFR-4 is significantly but not totally inhibited.
AZ8010 inhibits invasion in vitro.
We next examined the impact of AZ8010 on invasion using these same two PNT1a derived cell lines and the PNT1a control cells in defined medium with 
t-test). This result indicates that FGFs in serum and/or autocrine
FGFs from cancer cells drive a significant fraction of invasion by PCa cells, even in serum, which contains other growth factors. Treatment with 500 nM AZ8010 further decreased invasion somewhat compared 100 nM AZ8010 but the differences were not statistically significant.
Proliferation was decreased in FGF2 defined medium ( Figure 4C ) at both 100 nM and 500 nM AZ8010 but effects on proliferation were less pronounced than those on invasion (11-
38% inhibition of proliferation). Analysis of AZ8010 treated VCaP cells with Ki67
immunohistochemistry and TUNEL showed statistically significant decreases in Ki67 staining and increases in TUNEL at both doses (Supplementary Figure 1) . Similar results were seen with
PC3 and LNCaP cells (data not shown). No statistically significant effect on proliferation was
seen on PCa cell lines in serum containing medium (data not shown). Of note, PC3 which express higher levels of FGFR-4 than VCaP (Fig 1) , showed similar responses to both 100 nM and 500nM AZ8010, indicating that higher FGFR-4 expression does not contribute significantly to resistance to AZ8010 at these levels of drug.
AZ8010 inhibits tumor growth in vivo.
We then tested the anti-tumor activity of the AZ8010 using VCaP cells expressing luciferase in vivo. Two weeks after subcutaneous injection in nude mice, animals were treated with AZ8010 at 12.5 mg/kg/day by oral gavage or vehicle only.
Tumors were collected 4 hours after the last drug treatment. As seen in Fig 5A, this treatment resulted in nearly complete inhibition of tumor growth by luciferase imaging. Mean tumor weight after 4 weeks of treatment was significantly decreased (Fig 5B) ; 194 mg for treated tumors Vs 910 mg for controls, (p=.01, Mann-Whitney). No toxicity was detected and mouse weights were stable throughout this experiment and no differences were seen in body weight between the treated and control groups (Fig 5B) . Tumor sections were then analyzed using IHC for Ki67 to evaluate proliferation and CD31 to evaluate angiogenesis. Apoptosis was evaluated by TUNEL and all three markers were quantitated using image analysis (Fig 5C) . Ki67 staining was decreased by 22% (p<0.01, Mann-Whitney) while TUNEL was increased by almost 250% (Fig 6A) and quantitative analysis of Western blots showed a 95% decrease in band intensity relative to controls (p<.04, t test). Western blots of tumor extracts were also analyzed for alterations of MEK phosphorylation (Fig 6B) , which is upstream of ERK.
MEK phosphorylation was visibly decreased and by quantitative analysis of Western blots there was a 56% decrease in band intensity relative to controls (p<.01, t-test). ERK phosphorylation (Fig 6C) was also significantly inhibited and, by quantitative analysis, band intensity was decreased by 84% (p<0.02, t-test). Thus the predicted targets show significant inhibition in vivo in tumors treated with AZ8010. Interestingly, we saw no alteration in AKT phosphorylation in treated tumors (Fig 6D) , although in some systems AKT activation is downstream of FGFR signaling. Concordant with this observation, we observed no decrease in AKT activation upon treatment with AZ8010 in PC3 and FGFR-4 expressing PNT1a cells (Supplementary Fig 3) .
Thus ERK, rather than AKT, seems to be the critical target of AZ8010 in vivo.
Research. 
DISCUSSION
Based on correlative studies in human tissue samples and animal model studies, FGFR signaling is a promising therapeutic target in PCa. Our studies with AZ8010 support this concept. It should be noted that reported analyses to date do not show high level amplification or point mutations of FGFRs in PCa tissues, in contrast to the findings in other malignancies such as gastric cancer (amplification) or bladder cancer (point mutation). In PCa there is overexpression of multiple FGF ligands, increased receptor expression, association of progression with germline polymorphisms that enhance signaling and downregulation of FGF signaling inhibitors (2) . Thus while somatic DNA structural alterations are reliable indicators of susceptibility to targeted agents in many cases, other alterations can also be indicative of involvement of a specific signaling pathway in cancer progression.
One interesting aspect of our in vitro studies is our finding that the FGFR inhibitor had significant effects on invasion in all cell lines tested while effects on proliferation were significantly weaker. However, net cell growth in vivo was markedly inhibited by FGFR inhibition.
It is interesting to note that the TMPRSS2/ERG fusion gene, which is present in 40-60% of human PCas, strongly promotes invasion in vitro but has more limited affects on proliferation in vitro and yet when it is knocked down with shRNA, tumor progression in vivo is significantly inhibited (35) . One interpretation of these findings is that invasive capacity is required for tumor growth in vivo and that effects on proliferation in vitro may not necessarily reflect the ability of a drug or knockdown of a gene target to inhibit tumor progression in vivo.
In addition to direct effects on tumor invasion in PCa, inhibition of FGFR signaling has significant effects on the tumor microenvironment, either directly or indirectly. One major target 
inhibition that could inhibit secretion of paracrine factors that promote angiogenesis. For example, VEGF has been shown to be induced by FGF signaling in some systems (38) .
Similarly, FGF signaling also plays a role in myofibroblast promotion of PCa progression, in part by enhancing angiogenesis (39) . It is likely that the decreased proliferation and increased cell death seen in the treated tumors in vivo is in part due to inhibition of angiogenesis and other microenvironmental effects and this accounts for some of the difference between in vitro and the in vivo affects on net proliferation. It is also possible that these effects may be due to changes in the biology of the cancer cells themselves when growing in an in vivo context. One potential explanation is that in tumors the effective FGF concentration is higher due to binding of secreted FGFs by extracellular matrix proteins within the tumor. Further studies are needed to understand in detail the importance of different activities in the observed tumor growth inhibition.
As noted above, AZ8010 inhibits VEGFR2 activation at an IC50 of greater than 200 nM.
VEGFR2 is expressed on endothelial cells and promotes angiogenesis (40) so that it is possible that some of the effects seen on angiogenesis are a result of inhibit of endothelial VEGFR2.
However, two hours after oral administration of AZ8010 in nude mice free serum levels of the drug are approximately 170 nM and 64 nM by 4 hours, with levels following to 3 nM at 24 hours after treatment (unpublished data). Thus any inhibition of endothelial VEGFR2 (and VEGFR2 on PCa cells) is likely to be quite transient using a daily drug administration. Thus while inhibition of endothelial VEGFR2 may play a role in the effects seen in vivo, it is likely to be minor. Overall, it is likely that the vast majority of the antitumor effects of AZD81010 in vivo can be accounted for by FGFR inhibition but further studies are needed to clarify this point. Of course, from a clinical point of view, some VEGFR2 inhibition is not a negative attribute for a cancer therapeutic.
We have previously shown that ERK activation is a major downstream target of activated FGFRs and ERK activation strongly promotes PCa cell invasion in vitro (26) . A striking result of our studies is that the vast majority of ERK activation in VCaP cells in vivo (>80%) can be AZ8010 is highly chemically related to a newer generation FGFR inhibitor AZD4547 (33), and its properties in vitro are almost identical to AZD4547, but it has inferior pharmacokinetic properties. As described above, two hours after administration of AZD8010 serum levels are approximately 170 nM and falls to 3 nM by 24 hours after administration. Thus effective drug concentrations that can inhibit FGFR-4, and to a lesser extent FGFR-1, are not maintained for the entire 24 hours between drug administrations in our studies. This almost certainly decreases its potential efficacy and it is likely that AZD4547 will be more potent in vivo in targeting PCa expressing higher levels of FGFR-4. AZD4547 is currently undergoing Phase I clinical trials in patients with advanced cancers. Our studies suggest that the AZD4547 may be useful in the treatment of aggressive PCa at various clinical stages. 
